ViroPharma 8-K 2006
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): April 13, 2006
(Exact Name of Registrant as Specified in its Charter)
397 EAGLEVIEW BOULEVARD, EXTON, PENNSYLVANIA 19341
(Address of Principal Executive Offices including Zip Code)
(Registrants Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Item 1.01 Entry into a Material Definitive Agreement
On April 13, 2006, ViroPharma Incorporated (ViroPharma) and Alpharma Inc. (Alpharma) entered into a Bulk Supply Agreement (the Supply Agreement) related to the manufacture and supply by Alpharma to ViroPharma of the active pharmaceutical ingredient of Vancocin® (the API). The Supply Agreement contains the general ordering and commercial supply terms and conditions as well as the specific economic terms for purchase of API including price and minimum purchase requirements.
Item 7.01 Regulation FD Disclosure
ViroPharma also announced that the API manufactured by Alpharma and the Vancocin finished product manufactured by OSG Norwich Pharmaceuticals, Inc. have been qualified by the U.S. Food and Drug Administration and the validation of its third party supply chain for Vancocin has been completed. A copy of the press release is set forth as Exhibit 99.1 attached hereto.
Item 9.01. Financial Statements and Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.